The use of 3 biomarkers – cystatin-C (Cys-C), retinol-binding protein (RBP), and ischemia-modified albumin (IMA) – for the clinical classification and outcome of coronary heart disease (CHD) has not been adequately evaluated. Here, CST3 is linked to coronary artery disorder.